RVMD ▼ -6.3% - Revolution Medicines, Inc. $RVMD RBC Capital notes Revolution Medicines looks to be down in response to yesterday's disclosure of FDA's Rasonque review documents, particularly the ORR data disclosed for the drug across RAS mutant subpopulations, but the firm views the pullback as an "overreaction" and thinks the focus on response rate when OS data is available is "not appropriate." Given a drug that is approved on "a highly clinically meaningful benefit" and looking at a potential strong first quarter of launch, the firm would be buyers on weakness into Q3 earnings and keeps an Outperform rating and $259 price target on Revolution shares. 08-OCT-2026 03:52 PM ET